ProCE Banner Activity

CME

Contemporary and Future Strategies in Myelofibrosis: Applying New Evidence to Personalize Care

Video

Watch this on-demand webcast from a June 2023 symposium featuring Ruben A. Mesa, MD; John Mascarenhas, MD; and Brady L. Stein, MD, MHS, on using evidence-based and guideline-directed best practices in caring for patients with myelofibrosis.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: June 21, 2023

Expiration: June 20, 2024

No longer available for credit.

Share

Faculty

John Mascarenhas

John Mascarenhas, MD

Director
Center of Excellence in Blood Cancers and Myeloid Disorders
Director
Adult Leukemia Program
Leader
Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

Ruben A. Mesa

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Brady L. Stein

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AbbVie, Inc., CTI BioPharma, GSK, and Incyte Corporation.

AbbVie, Inc.

CTI BioPharma

GSK

Incyte Corporation

Target Audience

This program is intended for hematologists/oncologists and other healthcare professionals treating patients with myelofibrosis.

Program Learning Goal

This program aims to improve learners’ knowledge, confidence, competence, and performance in using evidence-based and guideline-directed best practices in caring for patients with myelofibrosis.

Learning Objectives

Upon completion of this activity, participants should be able to:

  • Incorporate available and emerging therapeutic strategies into the best-practice management of first-line therapy for patients with MF based on available data and expert recommendations, taking risk stratification, molecular features, cytogenetics, and symptom burden 

  • Appraise available and emerging clinical trial findings with novel agent for patients with MF, including those with disease-related anemia or for those with MF and severe thrombocytopenia

  • Recognize the symptoms and patterns of suboptimal first-line treatment response in patients with MF, including treatment intolerance and treatment resistance

  • Plan evidence-based therapeutic strategies for patients with MF and suboptimal response to first-line JAK inhibitor therapy 

  • Assess the tolerability profiles of current and emerging MF therapies and formulate an adverse effect management plan to support quality of life and continuation of treatment

  • Recall new data with agents and strategies currently under investigation to aid discussions of ongoing trial opportunities with eligible patients

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

John Mascarenhas, MD

Director
Center of Excellence in Blood Cancers and Myeloid Disorders
Director
Adult Leukemia Program
Leader
Myeloproliferative Disorders Clinical Research Program
Division of Hematology/Oncology
Tisch Cancer Institute
Professor of Medicine
Icahn School of Medicine at Mount Sinai
New York, New York

John Mascarenhas, MD: consultant/advisor/speaker: AbbVie, Bristol-Myers Squibb, Celgene, CTI Bio, Geron, GlaxoSmithKline, Imago, Incyte, Kartos, Kayropharm, MorphoSys, Novartis, Pfizer, PharmaEssentia, Sierra; researcher: AbbVie, Bristol-Myers Squibb, Celgene, CTI Bio, Geron, Incyte, Novartis.

Ruben A. Mesa, MD

President
Enterprise Cancer Service Line
Executive Director
Atrium Health Wake Forest Baptist Comprehensive Cancer Center
Enterprise Senior Vice President
Atrium Health
Vice Dean for Cancer Programs
Wake Forest University School of Medicine
Professor of Medicine
Wake Forest University School of Medicine
Winston-Salem, North Carolina

Ruben A. Mesa, MD, FACP: consultant/advisor/speaker: AbbVie, Blueprint, Bristol-Myers Squibb, CTI, Incyte, Sierra, Telios; researcher: Blueprint, CTI, GlaxoSmithKline, Imago, Incyte, Ionis, Morphosys, Pharmessentia.

Brady L. Stein, MD, MHS

Professor of Medicine
Department of Hematology/Oncology
Northwestern University Feinberg School of Medicine
Chicago, Illinois

Brady L. Stein, MD, MHS, has no relevant financial relationships to disclose. 

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Instructions for Credit

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, learners must follow these steps during the period from June 21, 2023, through June 20, 2024:

  1. Login or Sign Up for an account by clicking at the top of this page.
  2. Read the target audience, learning objectives, and faculty disclosures.
  3. View and study the content in its entirety.
  4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65 and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "My Certificates" page. There are no costs/fees for this activity.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.